Showing results (2351-2360 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|September 9, 2018
One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State ValuationBrendan Mulhern, Richard Norman, Deborah J Street, et al.
Pharmacoeconomics|February 16, 2010
Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility IndexMurali Sundaram, Michael J Smith, Dennis A Revicki, et al.
Pharmacoeconomics|September 18, 2016
Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice RecommendationsObinna I Ekwunife, James F O'Mahony, Andreas Gerber Grote, et al.
Pharmacoeconomics|September 25, 2016
Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UKRichard Lawson, James Ryan, Frederic King, et al.
Pharmacoeconomics|September 5, 2016
A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the EvidenceRos Wade, Robert Hodgson, Mousumi Biswas, et al.
Pharmacoeconomics|May 1, 2017
Verification of Decision-Analytic Models for Health Economic Evaluations: An OverviewErik J Dasbach, Elamin H Elbasha
Pharmacoeconomics|November 6, 2009
The future of health technology assessment in healthcare decision making in AsiaBong-Min Yang
Pharmacoeconomics|December 18, 2009
Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluationEric Deconinck, Houda Miadi-Fargier, Claude Le Pen, et al.
Pharmacoeconomics|December 18, 2009
Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the USVirginia M Rosen, Douglas C A Taylor, Hemangi Parekh, et al.
Pharmacoeconomics|December 18, 2009
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testingLisa M Meckley, James M Gudgeon, Jeffrey L Anderson, et al.
Pageof 336